Tagged with P

Global Healthcare is finally moving from a reactive “machine” to a proactive shield. In the latest issue of ISPOR’s Value & Outcomes Spotlight, Editor-in-Chief Zeba M. Khan, PhD, examines how Real-World Evidence is providing the definitive proof that prevention is now an economic and medical necessity.   For decades, the guiding…

Taiwan Promoted to General Manager of Moderna Taiwan in 2024, Wenchi Liu brings over 20 years of pharmaceutical industry experience spanning commercial strategy and operations. Since joining Moderna in 2023, she has helped position Taiwan as a priority market within the company’s Asia-Pacific region. In this interview, she discusses the rollout…

USA Frank Bedu‑Addo shares his journey from scientist to co‑founder and CEO of PDS Biotechnology. He highlights promising progress across PDS’s oncology pipeline, including strategic decisions that have helped improve antitumor efficacy through combination therapy, validate science through partnerships with leading institutions, and accelerate timelines to potential regulatory approval. Bedu‑Addo goes…

USA Orla Cloak, CEO of Minaris, explains how the organisation. was formed by integrating Minaris Regenerative Medicine, a dedicated cell and gene therapy (CGT) CDMO, and WuXi Advanced Therapies, which brought both CGT manufacturing and established GMP biosafety testing capabilities. Today, Minaris operates under private equity as two complementary businesses: Minaris…

Hong Kong Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He traces the organisation’s evolution from US-based acquisitions to a protein/peptide and circular RNA vaccine platform built in Hong Kong, explains…

China Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its CD7-targeted CAR-T programme, its strategy to translate complex cell therapies into viable commercial products, and how PersonGen is repositioning its…

USA 2026 could mark a turning point for biosimilar adoption in the US. By scrapping requirements for redundant clinical trials and pushing Congress to end the “Interchangeable” label, the FDA has cleared the runway for biosimilars. However, with PBM “rebate walls” and patent thickets still standing, will these lower cost therapies…

Taiwan Professor Yun-Ching Fu serves as Superintendent of Taichung Veterans General Hospital, Taiwan’s largest national medical centre in the central region. A paediatric interventional cardiologist by training, Professor Fu established Taiwan records for minimally invasive cardiac defect repair and now leads a 1,632-bed institution serving 10,000 outpatients daily. Under his leadership,…

Hong Kong Hong Kong is at a strategic inflection point as it seeks to redefine its role in global life sciences through regulatory credibility, institutional design, and long-term positioning between China and international markets. Industry stalwart Lo Yuk Lam reflects on how regulation, talent, capital markets, and national planning intersect to shape…

Hong Kong Anirvan Dutt Chaudhuri, General Manager of Novo Nordisk Hong Kong, brings nearly 15 years of commercial leadership experience across global markets including Denmark, Switzerland, the US, Turkey, and now Hong Kong. Since arriving in 2024, he has transformed the local affiliate by building critical functions, expanding cross-border collaboration, and driving…

MEA Dr Said Ismail, geneticist and professor of genomics at Hamad Bin Khalifa University, reflects on his role as the founding director and one of the architects of the Qatar Genome Programme (QGP), one of the Middle East’s most established and globally recognised population‑level genomics initiatives. He describes the pivotal decisions…

USA David Barrett has led the American Society of Gene & Cell Therapy (ASGCT) since 2018, guiding its evolution into the leading professional body for scientists, clinicians, industry leaders and patient advocates in cell and gene therapy. Founded in 1996, ASGCT now sits at the centre of research, education and policy…